3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Conditions
Lung Cancer Metastatic
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
191
pembrolizumab
155
Pemetrexed
134
Cisplatin
117
durvalumab
71
Paclitaxel
71
osimertinib
67
Nivolumab
66
Docetaxel
63
Specimen Handling
61
atezolizumab
57
Magnetic Resonance Spectroscopy
50
Etoposide
46
Gemcitabine
42
Radiotherapy
39
Radiosurgery
37
130-nm albumin-bound paclitaxel
34
Drug Therapy
30
Cetuximab
28
Bevacizumab
27
Ipilimumab
25
Taxes
23
cemiplimab
22
tislelizumab
20
Platinum
20
amivantamab
18
Radiation
18
Immunoglobulin G
17
1,2-diaminocyclohexaneplatinum II citrate
17
Disulfides
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
evolocumab
×
Thoracic
×
90 days
×
Clear all
NCT03337698
2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2
Terminated
314 enrolled
31 charts
NCT05144529
2026-05-05
TOP2101
Duke University
Phase 2
Terminated
19 enrolled
16 charts